Physician profile
Don D Son
NPI 1558564898
$11,839.99
in general payments reported to CMS, 2019-2025
29 companies · $1,726 in 2025
The $1,726 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,707 · 2020: $1,289 · 2021: $2,144 · 2022: $1,774 · 2023: $1,652 · 2024: $1,548 · 2025: $1,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,925.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,398.18 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $1,546.03 | 2019-2025 | Linzess, Viberzi, Creon |
| Novartis Pharmaceuticals Corporation | $1,251.86 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $913.39 | 2019-2025 | Farxiga, Airsupra |
| Nestle Healthcare Nutrition INC. | $806.38 | 2020-2023 | |
| Novo Nordisk INC | $720.81 | 2021-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $646.75 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $632.22 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Aimmune Therapeutics, INC. | $512.67 | 2024-2025 | Zenpep |
| Allergan, INC. | $420.72 | 2019-2020 | |
| Ibsa Pharma INC. | $366.90 | 2021-2025 | Tirosint, Licart, Flector |
| Amarin Pharma, INC. | $276.11 | 2019-2022 | |
| Vivus LLC | $234.23 | 2021-2025 | Pancreaze, Qsymia |
| Erbe USA INC | $178.12 | 2019 | |
| Pfizer INC. | $130.82 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $111.47 | 2023-2025 | Cologuard Collection Kit |
| Radius Health, INC. | $108.85 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.73 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $91.98 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $68.82 | 2025 | Verquvo |
| Astellas Pharma US INC | $59.90 | 2019-2020 | |
| Redhill Biopharma INC. | $52.19 | 2020-2021 | |
| Lundbeck LLC | $49.43 | 2025 | Rexulti |
| Shield Therapeutics INC | $34.66 | 2023 | Accrufer |
| Biohaven Pharmaceuticals, INC. | $34.64 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $32.14 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $27.44 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $22.45 | 2024 | Zoryve |
| Glaxosmithkline, LLC. | $14.10 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Son listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.